**Appendix 3. Clinical Characteristics and Outcomes of Definite and Probable Cases**

|  |  |
| --- | --- |
| Hospital-onset criteria |  |
|  Definite | 7 (6%) |
|  Probable | 107 (94%) |
| Symptomatic  | 80 (70%) |
| Reason for Testing: |  |
|  New symptoms | 47 (41%) |
|  Pre-op/Pre-procedure | 27 (24%) |
|  Discharge Planning | 27 (24%) |
|  Cluster Investigation | 7 (6%) |
|  Readmission | 1 (1%) |
|  Other | 5 (4%) |
| Received Treatment\*  | 60 (53%) |
| Immunocompromised§ | 50 (44%) |
| Unvaccinated | 28 (25%) |
| Outcome: |  |
|  Death | 16 (14%) |
|  ICU | 14 (12%) |

\*Remdesivir, nirmatrelvir/ritonavir, mAb, or dexamethasone (if new or increased dose for COVID-19)

§Active chemotherapy, hematologic or solid organ transplant, current steroid use of ≥20mg prednisone/day or equivalent